Home LiteratureArticle Details
PMID: 17671652 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.

The Journal of clinical investigation ·Vol. 117 ·No. 8 ·2007-08-00 ·Pages 2225-32

Deichmann A, Hacein-Bey-Abina S, Schmidt M, Garrigue A, Brugman MH, Hu J, Glimm H, Gyapay G, Prum B, Fraser CC, Fischer N, Schwarzwaelder K, Siegler ML, de Ridder D, Pike-Overzet K, Howe SJ, Thrasher AJ, Wagemaker G, Abel U, Staal FJ, Delabesse E, Villeval JL, Aronow B, Hue C, Prinz C, Wissler M, Klanke C, Weissenbach J, Alexander I, Fischer A, von Kalle C, Cavazzana-Calvo M

Abstract

Recent reports have challenged the notion that retroviruses and retroviral vectors integrate randomly into the host genome. These reports pointed to a strong bias toward integration in and near gene coding regions and, for gammaretroviral vectors, around transcription start sites. Here, we report the results obtained from a large-scale mapping of 572 retroviral integration sites (RISs) isolated from cells of 9 patients with X-linked SCID (SCID-X1) treated with a retrovirus-based gene therapy protocol. Our data showed that two-thirds of insertions occurred in or very near to genes, of which more than half were highly expressed in CD34(+) progenitor cells. Strikingly, one-fourth of all integrations were clustered as common integration sites (CISs). The highly significant incidence of CISs in circulating T cells and the nature of their locations indicate that insertion in many gene loci has an influence on cell engraftment, survival, and proliferation. Beyond the observed cases of insertional mutagenesis in 3 patients, these data help to elucidate the relationship between vector insertion and long-term in vivo selection of transduced cells in human patients with SCID-X1.

MeSH Terms
Antigens, CD34 Cell Proliferation Cell Survival/genetics Gammaretrovirus Genetic Therapy Genetic Vectors Genome, Human Hematopoietic Stem Cells/metabolism Humans Lymphopoiesis/genetics Mutagenesis, Insertional Quantitative Trait Loci T-Lymphocytes Time Factors Virus Integration/genetics X-Linked Combined Immunodeficiency Diseases/genetics,therapy
Chemicals
Antigens, CD34
Authors & Affiliations
32 authors, click to expand affiliations / ORCID
Deichmann Annette
Institute for Molecular Medicine and Cell Research and Department of Internal Medicine I, German Cancer Research Center, University of Freiburg, Freiburg, Germany.
Hacein-Bey-Abina Salima
Schmidt Manfred
Garrigue Alexandrine
Brugman Martijn H
Hu Jingqiong
Glimm Hanno
Gyapay Gabor
Prum Bernard
Fraser Christopher C
Fischer Nicolas
Schwarzwaelder Kerstin
Siegler Maria-Luise
de Ridder Dick
Pike-Overzet Karin
Howe Steven J
Thrasher Adrian J
Wagemaker Gerard
Abel Ulrich
Staal Frank J T
Delabesse Eric
Villeval Jean-Luc
Aronow Bruce
Hue Christophe
Prinz Claudia
Wissler Manuela
Klanke Chuck
Weissenbach Jean
Alexander Ian
Fischer Alain
von Kalle Christof
Cavazzana-Calvo Marina
References (32)
32 references, click to expand
  1. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease.
    Science. 2000 Apr 28;288(5466):669-72 PMID: 10784449
  2. Gammaretrovirus-mediated correction of SCID-X1 is associated with skewed vector integration site distribution in vivo.
    J Clin Invest. 2007 Aug;117(8):2241-9 PMID: 17671654
  3. Comprehensive genome sequence analysis of a breast cancer amplicon.
    Genome Res. 2001 Jun;11(6):1034-42 PMID: 11381030
  4. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy.
    N Engl J Med. 2002 Apr 18;346(16):1185-93 PMID: 11961146
  5. Correction of ADA-SCID by stem cell gene therapy combined with nonmyeloablative conditioning.
    Science. 2002 Jun 28;296(5577):2410-3 PMID: 12089448
  6. HIV-1 integration in the human genome favors active genes and local hotspots.
    Cell. 2002 Aug 23;110(4):521-9 PMID: 12202041
  7. New genes involved in cancer identified by retroviral tagging.
    Nat Genet. 2002 Sep;32(1):166-74 PMID: 12185365
  8. High-throughput retroviral tagging to identify components of specific signaling pathways in cancer.
    Nat Genet. 2002 Sep;32(1):153-9 PMID: 12185366
  9. Genome-wide retroviral insertional tagging of genes involved in cancer in Cdkn2a-deficient mice.
    Nat Genet. 2002 Sep;32(1):160-5 PMID: 12185367
  10. Polyclonal long-term repopulating stem cell clones in a primate model.
    Blood. 2002 Oct 15;100(8):2737-43 PMID: 12351380
  11. Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells.
    Blood. 2003 Mar 15;101(6):2191-8 PMID: 12424203
  12. Clonality analysis after retroviral-mediated gene transfer to CD34+ cells from the cord blood of ADA-deficient SCID neonates.
    Nat Med. 2003 Apr;9(4):463-8 PMID: 12640448
  13. Transcription start regions in the human genome are favored targets for MLV integration.
    Science. 2003 Jun 13;300(5626):1749-51 PMID: 12805549
  14. LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
    Science. 2003 Oct 17;302(5644):415-9 PMID: 14564000
  15. Targeting survival: integration site selection by retroviruses and LTR-retrotransposons.
    Cell. 2003 Oct 17;115(2):135-8 PMID: 14567911
  16. Chromosomes, genes, and development of testicular germ cell tumors.
    Cancer Genet Cytogenet. 2004 Jun;151(2):93-138 PMID: 15172750
  17. Advances in biology of multiple myeloma: clinical applications.
    Blood. 2004 Aug 1;104(3):607-18 PMID: 15090448
  18. Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences.
    PLoS Biol. 2004 Aug;2(8):E234 PMID: 15314653
  19. Transcriptionally active genome regions are preferred targets for retrovirus integration.
    J Virol. 1990 Feb;64(2):907-12 PMID: 2296087
  20. Retroviral integration sites in transgenic Mov mice frequently map in the vicinity of transcribed DNA regions.
    J Virol. 1990 Jun;64(6):3056-8 PMID: 2335826
  21. A model for predicting the risk of cancer consequent to retroviral gene therapy.
    Hum Gene Ther. 1992 Oct;3(5):479-86 PMID: 1420447
  22. Distinct genomic integration of MLV and SIV vectors in primate hematopoietic stem and progenitor cells.
    PLoS Biol. 2004 Dec;2(12):e423 PMID: 15550989
  23. Gene therapy of X-linked severe combined immunodeficiency by use of a pseudotyped gammaretroviral vector.
    Lancet. 2004 Dec 18-31;364(9452):2181-7 PMID: 15610804
  24. Relationship between retroviral DNA-integration-site selection and host cell transcription.
    Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1436-41 PMID: 15659548
  25. Clonal evidence for the transduction of CD34+ cells with lymphomyeloid differentiation potential and self-renewal capacity in the SCID-X1 gene therapy trial.
    Blood. 2005 Apr 1;105(7):2699-706 PMID: 15585650
  26. Clonal dominance of hematopoietic stem cells triggered by retroviral gene marking.
    Science. 2005 May 20;308(5725):1171-4 PMID: 15905401
  27. New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling.
    J Exp Med. 2005 Jun 6;201(11):1715-23 PMID: 15928199
  28. Recurrent retroviral vector integration at the Mds1/Evi1 locus in nonhuman primate hematopoietic cells.
    Blood. 2005 Oct 1;106(7):2530-3 PMID: 15933056
  29. Insertional mutagenesis identifies genes that promote the immortalization of primary bone marrow progenitor cells.
    Blood. 2005 Dec 1;106(12):3932-9 PMID: 16109773
  30. The role of LMO2 in development and in T cell leukemia after chromosomal translocation or retroviral insertion.
    Mol Ther. 2006 Jan;13(1):15-25 PMID: 16260184
  31. Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells.
    Proc Natl Acad Sci U S A. 2006 Jan 31;103(5):1457-62 PMID: 16432223
  32. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1.
    Nat Med. 2006 Apr;12(4):401-9 PMID: 16582916
Article Info
Journal
The Journal of clinical investigation
Abbr.
J Clin Invest
ISSN
0021-9738
Published
2007-08-00
Pages
2225-32
Language
English
Region
United States
NLM ID
7802877
PMCID
PMC1934585
Subset
IM
Grants
NCI NIH HHS · R01 CA112470-01 · United States
Corrections
CommentIn
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com